Forest plot of the risk of nasopharyngeal carcinoma associated with the CCND1 G870A polymorphism.

<p>A, the alleles model (A vs. G); B, the co-dominant model (AA vs. GG); C, the dominant model (AA/AG vs. GG); D, the recessive model (AA vs. AG/GG). Error bars indicate 95% CI. Solid squares represent each study in the meta-analysis. Solid diamonds represent pooled OR.</p

Begger’s funnel plots for publication bias of the meta-analysis on the association between CCND1 G870A polymorphism and NPC risk in co-dominant model (AA vs. GG).

<p>Begger’s funnel plots for publication bias of the meta-analysis on the association between CCND1 G870A polymorphism and NPC risk in co-dominant model (AA vs. GG).</p

Influence analysis for the co-dominant model (AA vs. GG) in the overall meta-analysis.

<p>This figure shows the influence of individual studies on the summary OR. The middle vertical axis indicates the overall OR and the two vertical axes indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of the dotted lines represent the 95% CI.</p

Meta-analysis of cylin D1(CCND1) polymorphism and risk of NPC.

<p>Abbreviations: CI, confident interval; OR, odd ratio; R, random model; F, fixed model.</p><p>Meta-analysis of cylin D1(CCND1) polymorphism and risk of NPC.</p

The characteristics of the included studies in the meta analysis.

<p>The characteristics of the included studies in the meta analysis.</p

Additional file 2 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 2. Figure S2: Kaplan–Meier survival analysis for OS in patients receiving adjuvant chemotherapy at stage II (A). DFS(B) and OS(C) in patients receiving adjuvant radiotherapy at stage I

Additional file 1 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 1. Figure S1: Kaplan–Meier survival analysis for OS in patients receiving adjuvant chemotherapy at stage I (A). DFS(B) and OS(C) in patients receiving adjuvant radiotherapy at stage

Additional file 6 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 6. Figure S6: Kaplan–Meier survival analysis for OS according to ECOG PS≥2 (A), stage III-IV (B) , high level of EBV-DNA (C), liver metastasis (D) and bone metastasis (E

Additional file 5 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 5. Figure S5: Kaplan–Meier survival analysis for OS in patients receiving anti- angiogenesis (A) and anti- EGFR (B) therapy at stage IV or after relapsed. Kaplan–Meier survival analysis for PFS in patients receiving anti-angiogenesis (C) and anti-EGFR (D) therapy at stage IV or after relapse

Additional file 3 of Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

Additional file 3 Supplement Figure 3 Kaplan–Meier survival analysis for OS in patients receiving adjuvant radiotherapy at stage III (A). DFS(B) and OS(C) in patients receiving adjuvant chemotherapy at stage II